Comparison of 25 and 75 mg/day naftopidil for lower urinary tract symptoms associated with benign prostatic hyperplasia: A prospective, randomized controlled study

International Journal of Urology

Volumn 13, Issue 7, 2006, Pages 932-938

  Yokoyama, Teruhiko ^a   Kumon, Hiromi ^a   Nasu, Yoshitsugu ^b   Takamoto, Hitoshi ^c   Watanabe, Toyohiko ^d  

^a OKAYAMA UNIVERSITY   (Japan)

^b Kochi Health Sciences Center   (Japan)

^c University of Tokyo   (Japan)

^d OKAYAMA SAISEIKAI GENERAL HOSPITAL   (Japan)

Author keywords

Benign prostatic hyperplasia; Lower urinary tract symptoms; Naftopidil; Optimal dose

Indexed keywords

ALPHA 1D ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; NAFTOPIDIL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; GAIT DISORDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MICTURITION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESIDUAL URINE; SCORING SYSTEM; STOMACH DISCOMFORT; SYMPTOM; TREMOR; URINARY TRACT DISEASE; URINE FLOW RATE;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NAPHTHALENES; PIPERAZINES; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA; TREATMENT OUTCOME; URINATION DISORDERS; URODYNAMICS;

EID: 33745910846     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2006.01443.x     Document Type: Article

References (24)

1. Miyake O, Takahara S, Yoshimura K et al. Medical treatment for benign prostatic hyperplasia - evaluation of 50 mg fixed dose regimen of naftopidil. Jpn. J. Urol. Surg. 2001; 14: 363-71.
2. Yamaguchi O, Fukaya Y, Shiraiwa Y et al. Dose-dependent effects and clinical usefulness of naftopidil (KT-611) on urinary obstruction caused by benign prostatic hyperplasia - Double-blind comparative study compared with placebo. Kiso Rinsyo 1997; 31: 1315-60.
3. Carlson RV, Boyd KM, Webb DJ. The revision of the Declaration of Helsinki: past, present and future. Br. J. Clin. Pharmacol. 2004; 57: 695-713.
4. Zelen M. Randomized consent designs for clinical trials: an update. Stat. Med. 1990; 9: 645-56.
5. Torgerson DJ, Rolan M. What is Zelen's design? - Randomised controlled trial methods, part 4. BMJ 1998; 316: 606.
6. Hamma Y, Kawabe K, Tsukamoto T et al. Estimate criteria for efficacy of treatment in benign prostatic hyperplasia. Int. J. Urol. 1996; 3: 267-73.
7. 1-adrenoceptors. Jpn. J. Pharmacol. 1999; 79: 447-54.
8. Sugaya K, Nishijima S, Miyazato M, Ashitomi K, Hatano T, Ogawa Y. Effects of intrathecal injection of tamsulosin and naftopidil, alpha-1A and -1D adrenergic receptor antagonists, on bladder activity in rats. Neurosci. Lett. 2002; 328: 74-6.
9. Kojima Y, Sasaki S, Hayashi Y et al. Correlation between alpha 1-adrenoreceptor subtype mRNA expression level and efficacy of naftopidil for BPH patients. J. Urol. 2004; 171A: 242.
10. Nishino Y, Moriyama Y, Hagiwara N, Miwa Y, Deguchi T. A comparative crossover study for effectiveness of naftopidil and tamsulosin in patients with benign prostatic hyperplasia. Jpn. J. Neurogenic Bladder Soc. 2001; 12: 82.
11. Hayashi T, Sakai Y, Saito K et al. A comparative study assessing clinical effects of naftopidil and tamsulosin hydrochloride on benign prostatic hyperplasia. Hinyokika Kiyo 2002; 48: 7-11.
12. Ikemoto I, Kiyota H, Ohishi Y et al. Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two-drug crossover study. Int. J. Urol. 2003; 10: 587-94.
13. Masuda M, Hirokawa M, Furuhata A et al. Etiology of nocturia and clinical efficacy of naftopidil on nocturia in patients with benign prostatic hyperplasia. Hinyokika Kiyo 2004; 50: 309-14.
14. Yamada Y, Kaneko T, Takai K. The efficacy of naftopidil on lower urinary tract symptoms associated with benign prostatic hyperplasia. The difference between administration in the morning and the evening. Jpn. J. Urol. Surg. 2003; 16: 765-9.
15. Yano M, Kitahara S, Yasuda K et al. A pilot study evaluating a new questionnaire for prostatic symptom scoring, the SPSS, and its sensitivity as constructed to objective measures of outflow obstruction. Int. J. Urol. 2004; 11: 288-94.
16. Caine M. The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy. J. Urol. 1986; 136: 1-4.
17. Kawabe K, Ueno A, Takimoto Y et al. Use of an α1-blocker, YM617, in the treatment of benign prostatic hypertrophy. J. Urol. 1990; 144: 908-12.
18. Roehrborn CG. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. Urology 2001; 58: 953-9.
19. Kumamoto Y, Tsukamoto T, Tsuchida S et al. Clinical evaluation of terazosin hydrochloride on urinary obstruction caused by benign prostatic hypertrophy (I) - Dose finding study. Jpn. J. Urol. Surg. 1992; 5: 721-34.
20. Park YC, Nisshioka T, Kuria T et al. A multicenter, fixed-flexible dose study of terazosin hydrochloride in the treatment of the symptomatic benign prostatic hypertrophy. Hinyokika Kiyo 1992; 38: 857-68.
21. Fukaya Y, Shiraiwa Y, Yamaguchi O et al. Dose-finding study of naftopidil (KT-611) for bladder outlet obstruction caused by benign prostatic hypertrophy. Nishinihon J. Urol. 1992; 54: 697-710.
22. Yamanishi T, Yasuda K, Tojo M. Long term effects of naftopidil to benign prostatic hypertrophy. Jpn. J. Urol. Surg. 1992; 5: 359-63.
23. Oh-oka H, Katada A, Arakawa S et al. Clinical efficacy of naftopidil for benign prostatic hyperplasia. Jpn. J. Neurogenic Bladder Soc. 2001; 12: 179-88.
24. Lepor H, Williford WO, Barry M et al. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. J. Urol. 1998; 160: 1358-67.